Synthesis and activity of N-cyanoguanidine-piperazine P2X7 antagonists

被引：10

作者：

Betschmann, Patrick ^{[1
]}

Bettencourt, Brian ^{[1
]}

Donnelly-Roberts, Diana ^{[1
]}

Friedman, Michael ^{[1
]}

George, Jonathan ^{[1
]}

Hirst, Gavin ^{[1
]}

Josephsohn, Nathan ^{[1
]}

Konopacki, Donald ^{[1
]}

Li, Biqin ^{[1
]}

Maull, John ^{[1
]}

Morytko, Michael J. ^{[1
]}

Moore, Nigel StJohn ^{[1
]}

Namovic, Marian ^{[1
]}

Rafferty, Paul ^{[1
]}

Salmeron-Garcia, Jose-Andres ^{[1
]}

Tarcsa, Edit ^{[1
]}

Wang, Lu ^{[1
]}

Woller, Kevin ^{[1
]}

机构：

[1] Abbott Biores Ctr, Dept Med Chem, Worcester, MA 01605 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 14期

关键词：

P2X7; antagonists; cyanoguanidine; piperazine;

D O I：

10.1016/j.bmcl.2008.06.055

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel series of cyanoguanidine-piperazine P2X(7) antagonists were identified and structure-activity relationship (SAR) studies described. Compounds were assayed for activity at human and rat P2X(7) receptors in addition to their ability to inhibit IL-1 beta release from stimulated human whole blood cultures. Compound 27 possesses potent activity (0.12 mu M) in this latter assay and demonstrates moderate clearance in-vivo. (C) 2008 Elsevier Ltd. All rights reserved.

引用

下载

页码：3848 / 3851

页数：4

共 50 条

[41] Synthesis and SAR of novel 4,5-diarylimidazolines as potent P2X7 receptor antagonists
Merriman, GH
Ma, L
Shum, P
McGarry, D
Volz, F
Sabol, JS
Gross, A
Zhao, ZC
Rampe, D
Wang, L
Wirtz-Brugger, F
Harris, BA
Macdonald, D
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (02) : 435 - 438
[42] Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure Models
Fischer, Wolfgang
Franke, Heike
Kruegel, Ute
Mueller, Heiko
Dinkel, Klaus
Lord, Brian
Letavic, Michael A.
Henshall, David C.
Engel, Tobias
PLOS ONE, 2016, 11 (06):
[43] The P2X7 Receptor
Sluyter, Ronald
PROTEIN REVIEWS, VOL 19, 2017, 1051 : 17 - 53
[44] Discovery of highly functionalized scaffolds: Pyrroloimidazolediones as P2X7 receptor antagonists
Homerin, Germain
Lipka, Emmanuelle
Rigo, Benoit
Millet, Regis
Dezitter, Xavier
Furman, Christophe
Ghinet, Anna
TETRAHEDRON, 2017, 73 (35) : 5327 - 5336
[45] Synthesis and structure-activity relationships of novel, substituted 5,6-dihydrodibenzo[a,g]quinolizinium P2X7 antagonists
Lee, Ga Eun
Lee, Ho-Sung
Lee, So Deok
Kim, Jung-Ho
Kim, Won-Ki
Kim, Yong-Chul
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (03) : 954 - 958
[46] P2X7 receptor antagonists: a patent review (2010-2015)
Park, Jin-Hee
Kim, Yong-Chul
EXPERT OPINION ON THERAPEUTIC PATENTS, 2017, 27 (03) : 257 - 267
[47] Purinergic P2X7 receptor antagonists: Chemistry and fundamentals of biological screening
Gunosewoyo, Hendra
Coster, Mark J.
Bennett, Maxwell R.
Kassiou, Michael
BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (14) : 4861 - 4865
[48] Mechanism of action of species-selective P2X7 receptor antagonists
Michel, Anton D.
Ng, Sin-Wei
Roman, Shilina
Clay, William C.
Dean, David K.
Walter, Daryl S.
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 156 (08) : 1312 - 1325
[49] The scavenger activity of the human P2X7 receptor differs from P2X7 pore function by insensitivity to antagonists, genetic variation and sodium concentration: Relevance to inflammatory brain diseases
Ou, Amber
Gu, Ben J.
Wiley, James S.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2018, 1864 (04): : 1051 - 1059
[50] A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases
Arulkumaran, Nishkantha
Unwin, Robert J.
Tam, Frederick W. K.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (07) : 897 - 915

← 1 2 3 4 5 →